Clinical trialPhase 1Recruiting
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 2 June 2022
- Expected end
- 31 August 2030
- Enrollment
- 86 participants
- Sites
- 3
- Primary outcomes
- Incidence of Dose-Limiting Toxicities (DLTs); Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 25 September 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
Detailed description public domain (ClinicalTrials.gov)
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IMC-002. Multiple-dose levels of IMC-002 will be tested in subjects with advanced cancer.